Department of Cardiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Department of Obstetrics and Gynecology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Asian Pac J Cancer Prev. 2024 Sep 1;25(9):2979-2990. doi: 10.31557/APJCP.2024.25.9.2979.
Many types of cancer express the HER2/HER3 heterodimer, which is a crucial oncogenic unit. Research has shown that when these two biomarkers are expressed together, it correlates with higher tumor aggressiveness and lower overall survival rate. Therefore, many therapies have been developed to target both biomarkers simultaneously. This study aims to collect data on the co-expression levels of these biomarkers across different types of cancers.
A comprehensive search was conducted across PubMed, Scopus, Embase, and Web of Science databases to identify relevant studies. The event rates and their corresponding 95% confidence intervals were calculated. Heterogeneity, subgroup, and meta-regression analyses were conducted based on patients' residency region, age, and gender. The protocol of this study was registered in PROSPERO under ID: CRD42024504256.
We have detected 60 studies that met all of the inclusion criteria for our research. Out of these, we have focused on a total of 19 studies (with 6,079 participants) related to breast cancer, 9 studies (with 829 participants) related to lung cancer, 6 studies (with 1423 participants) related to gastric cancer, and 4 studies (with 802 participants) related to colorectal cancer for conducting our meta-analysis. According to our results, the co-expression rate of HER2 and HER3 in breast cancer patients is 18.5% (95%CI 11.7-27.9), in colorectal cancer patients is 17.1% (95%CI 2.4-63.4), in gastric cancer patients is 11.3% (95%CI 4.2-17.2), and in lung cancer patients is 12.7% (95%CI 5.2-22.8). The co-expression of HER2 and HER3 in lung cancer has a significant association with patients' gender (P=0.038).
The study found that HER2 and HER3 biomarkers, which are targets for different therapies, are co-expressed in various types of cancer.
许多类型的癌症表达 HER2/HER3 异二聚体，这是一种关键的致癌单位。研究表明，当这两种生物标志物同时表达时，与肿瘤侵袭性更高和总生存率更低相关。因此，已经开发了许多针对这两种生物标志物的同时靶向治疗方法。本研究旨在收集不同类型癌症中这些生物标志物共同表达水平的数据。
通过对 PubMed、Scopus、Embase 和 Web of Science 数据库进行全面检索，确定相关研究。计算事件发生率及其相应的 95%置信区间。根据患者居住地区、年龄和性别进行异质性、亚组和荟萃回归分析。本研究的方案已在 PROSPERO 中以 ID：CRD42024504256 进行注册。
我们共检测到符合研究纳入标准的 60 项研究。其中，我们重点关注了总共 19 项研究（共 6079 名参与者），涉及乳腺癌、9 项研究（共 829 名参与者）涉及肺癌、6 项研究（共 1423 名参与者）涉及胃癌和 4 项研究（共 802 名参与者）涉及结直肠癌进行荟萃分析。根据我们的结果，乳腺癌患者中 HER2 和 HER3 的共同表达率为 18.5%（95%CI 11.7-27.9），结直肠癌患者为 17.1%（95%CI 2.4-63.4），胃癌患者为 11.3%（95%CI 4.2-17.2），肺癌患者为 12.7%（95%CI 5.2-22.8）。肺癌中 HER2 和 HER3 的共同表达与患者性别显著相关（P=0.038）。
本研究发现，不同治疗靶点的 HER2 和 HER3 生物标志物在多种类型的癌症中共同表达。
Zotero 插件
